QUIT news

Latest 1 stories · newest Nov 10, 2026

QUIT

AchieveRx Reports Q3 2026 Financials, Launches New Brand, NDA Set for Q4

AchieveRx announced Q3 2026 results highlighting a corporate rebrand, strong 52-week clinical efficacy data for cytisinicline, and an on-track NDA resubmission as the company pivots to commercialization.

Earnings Nov 10, 2026 sentiment +0.50 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same QUIT feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/QUIT/newsSTART FREE